A Phase 3 interventional study of Odanacatib and Placebo for Odanacatib in Postmenopausal Osteoporosis, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-06-11.
Sponsored by Merck Sharp & Dohme LLC · Phase 3, Interventional, and Treatment
The purpose of the event-driven base study is to determine the safety and efficacy, especially fracture risk reduction, of odanacatib in postmenopausal women diagnosed with osteoporosis. In a placebo-controlled extension of the base study, participants continued to receive the same blinded study medication for a total of up to 5 years of blinded study medication combined between the base study and the extension. After participants received 5 years of blinded study medication, they received open-label odanacatib through the end of the first extension. Participants were then invited to enroll in a second extension study in which they received open-label odanacatib for an additional 5 years. Two imaging substudies (PN032-Base/Extension and PN035) were conducted for participants in the MK-0822-018 Study. Additional safety information was collected for participants who discontinued from the base study or the blinded first extension in an observational follow-up study, MK-0822-083 (EudraCT number: 2007-002693-66) .
1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.
This study's enrollment of 16,071 is above the median of 95 across 1,133 interventional studies indexed under Osteoporosis.
Browse Osteoporosis studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
Drug: Odanacatib · Dietary Supplement: Vitamin D3 · Dietary Supplement: Calcium carbonate
Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
Drug: Placebo for Odanacatib · Dietary Supplement: Vitamin D3 · Dietary Supplement: Calcium carbonate
50 mg tablet orally once weekly (OW)
Also known as: MK-0822
50 mg tablet orally OW
5600 IU orally OW
If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg
Also known as: Calcium supplements
Base Study: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture
Morphometric vertebral fractures were assessed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline and at Months 6, 12, and subsequent yearly time points. Incident fractures (i.e., occurring after baseline) in previously normal vertebral bodies and/or those occurring after baseline in previously fractured vertebral bodies (Genant semiquantitative \[SQ\] Grade 1-3) (T4 to L4) were confirmed by quantitative morphometric (QM) and either SQ or binary SQ (yes/no) methodologies. A time-to-event methodology was used to evaluate results: life-table estimates of the incidence proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and subsequent yearly intervals; an interval-censored approach was then used to determine incidence rate (number of participants with a morphometric fracture per 100 person-years of follow-up).
Time frame: Up to approximately 60 months of observation
Base Study: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated)
Osteoporotic clinical hip fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Hip fractures were fractures of the proximal femur confirmed as being located in the hip (i.e., sub-region not specified; cervical, and intertrochanteric). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 60 months of observation
Base Study: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated)
Osteoporotic non-vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur or shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 60 months of observation
Base Study + First Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture
Morphometric vertebral fractures were confirmed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline and at Months 6, 12, and subsequent yearly time points. Incident fractures (i.e., occurring after baseline) in previously normal vertebral bodies and/or those occurring after baseline in previously fractured vertebral bodies (Genant SQ Grade 1-3) (T4 to L4) were confirmed by QM and either SQ or binary SQ (yes/no) methodologies. A time-to-event methodology was used to evaluate results: life-table estimates of the incidence proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and subsequent yearly intervals; an interval-censored approach was then used to determine incidence rate (number of participants with a morphometric fracture per 100 person-years of follow-up).
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated)
Osteoporotic clinical hip fractures was confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Hip fractures were fractures of the proximal femur confirmed as being located in the hip (i.e., sub-region not specified; cervical, and intertrochanteric). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated)
Osteoporotic non-vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur and shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Rate of Adverse Events
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participants with adverse events (number of participants with an event per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Rate of Discontinuations From Study Treatment Due to an Adverse Event
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participant discontinuations from treatment due to adverse events (number of participants with an event per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension + Second Extension: Percent Change From Baseline in Bone Mineral Density (BMD) Measurements of the Total Hip
BMD was measured by dual-energy x-ray absorptiometry (DXA) at the total hip starting at screening, and at yearly intervals until the end of the study (second extension study) for all participants who entered the second extension study. Least squares (LS) means percent change in BMD from original baseline are provided through Month 108 (Year 9). At Months 96 (Year 8) and 108 (Year 9), approximately 3% or fewer participants in each treatment group had BMD data, and results at those time points should be viewed with caution. NOTE: The mean percent change in BMD from baseline in participants originally randomized to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in the base study.
Time frame: Baseline and once yearly, up to approximately 108 months of observation
Second Extension: Number of Participants Who Experienced an Adverse Event
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to approximately 34 months of observation
Second Extension: Number of Participants Discontinuing Study Treatment Due to an Adverse Event
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to approximately 34 months of observation
Imaging Substudy PN032-Base: Percent Change From Baseline in Volumetric Bone Mineral Density (vBMD) at the Lumbar Spine Using Quantitative Computed Tomography
Compartment-specific effects of osteoporosis were assessed by measuring trabecular vBMD at the lumbar spine (L1 total vertebral body) using quantitative computed tomography. The percent change from baseline at Month 24 (base study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in vBMD at the Lumbar Spine Using Quantitative Computed Tomography
Compartment-specific effects of osteoporosis were assessed by measuring trabecular vBMD at the lumbar spine (L1 total vertebral body) using quantitative computed tomography. The percent change from baseline at Month 60 (base study + extension study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 60
Sarcopenia Substudy PN035: Change From Baseline in Appendicular Lean Body Mass (aLBM)
Sarcopenia is the age-related loss of skeletal muscle mass and associated loss of strength. Progression of sarcopenia was assessed using aLBM as measured by total body DXA. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline and once yearly up to 4 years
Sarcopenia Substudy PN035: Change From Baseline in Short Physical Performance Battery (SPPB) Score
The Short Physical Performance Battery (SPPB) Score is used to assess physical function in older persons. The SPPB consists of 3 types of physical activities: standing balance, gait speed, and chair rise. Component activities are timed and then reduced to a categorical 0 to 4 scale based on time achieved. A higher composite score (range 0 to 12) indicates an improved function level. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline and once yearly up to 4 years
Sarcopenia Substudy PN035: Change From Baseline in Gait Speed
Gait speed is a component of the Short Physical Performance Battery (SPPB) Score. Participants are asked to walk a distance of 4 meters at their normal pace. The test is performed 2 times, and the walk done in the shortest time is used for scoring. The activity is timed and then reduced to a categorical 0 to 4 scale based on time achieved. Higher scores indicate an improved function level. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline and once yearly up to 4 years.
Base Study: Rate of Adverse Events
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participants with adverse events (number of participants with an event per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 60 months of observation
Base Study: Rate of Discontinuation From Study Treatment Due to an Adverse Event
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participant discontinuations from treatment due to adverse events (number of participants with an event per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 60 months of observation
Base Study: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated)
Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 60 months of observation
Base Study: Yearly Rate of Height Loss
Height was measured by wall-mounted stadiometer at randomization and at yearly intervals in the base study.
Time frame: Up to approximately 60 months of observation
Base Study: Number of Participants With Height Loss of > 1 cm
Height was measured by wall-mounted stadiometer at randomization and at yearly intervals in the base study.
Time frame: Baseline and once yearly, up to approximately 60 months of observation
Base Study: Percent Change From Baseline in BMD Measurements of the Total Hip
BMD was measured by DXA for all participants at the total hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study).
Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation
Base Study: Percent Change From Baseline in BMD Measurements of the Lumbar Spine
BMD was measured by DXA for all participants at the lumbar spine at randomization, Months 6, 12, and subsequent yearly intervals until the end of the study (base study). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses. at
Time frame: Baseline, Month 6, and once yearly, approximately 60 months of observation
Base Study: Percent Change From Baseline in BMD Measurements of the Femoral Neck
BMD was measured by DXA for all participants at the femoral neck-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study).
Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation
Base Study: Percent Change From Baseline in BMD Measurements of the Trochanter
BMD was measured by DXA for all participants at the trochanter-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study).
Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation
Base Study: Percent Change From Baseline in BMD Measurements of the Distal-Third Forearm
BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study) in an approximate 10% random subset of participants at selected sites.
Time frame: Baseline and once yearly, up to approximately 60 months of observation
Base Study: Percent Change From Baseline in BMD Measurements of the Lumbar Spine in Bisphosphonate-Intolerant Participants
BMD was measured by DXA in bisphosphonate-intolerant participants at the lumbar spine at randomization, and at yearly intervals until the end of the study (base study). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses. Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.
Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation
Base Study: Percent Change From Baseline in BMD Measurements of the Total Hip in Bisphosphonate-Intolerant Participants
BMD was measured by DXA in bisphosphonate-intolerant participants at the total hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.
Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation
Base Study: Percent Change From Baseline in BMD Measurements of the Femoral Neck in Bisphosphonate-Intolerant Participants
BMD was measured by DXA in bisphosphonate-intolerant participants at the femoral neck-hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.
Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation
Base Study: Percent Change From Baseline in BMD Measurements of the Trochanter in Bisphosphonate-Intolerant Participants
BMD was measured by DXA in bisphosphonate-intolerant participants at the trochanter-hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.
Time frame: Baseline, Month 6, and once yearly, up to approximately 60 months of observation
Base Study: Percent Change From Baseline in BMD Measurements of the Distal-Third Forearm in Bisphosphonate-Intolerant Participants
BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study) in an approximate 10% random subset of bisphosphonate-intolerant participants at selected sites. Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.
Time frame: Baseline and once yearly, up to approximately 60 months of observation
Base Study: Percent Change From Baseline in Serum C-Telopeptides of Type I Collagen (s-CTx) After Log-Transformation
s-CTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in s-CTx was determined using a longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
Time frame: Baseline, Month 6, and once yearly up to 4 years
Base Study: Percent Change From Baseline in Urinary N-Telopeptides of Type I Collagen/Creatinine (u-NTx/Cr) Ratio After Log-Transformation
u-NTx, a biochemical marker of bone resorption, was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. Urine NTx measurements (in bone collagen equivalents \[BCE\]) were normalized to urine Cr concentration (i.e., u-NTx/Cr ratio) and the log-transformed fraction from baseline in u-NTx/Cr ratio was then determined using a longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
Time frame: Baseline, Month 6, and once yearly up to 4 years
Base Study: Percent Change From Baseline in Bone-Specific Alkaline Phosphatase (BSAP) After Log-Transformation
BSAP is an enzyme produced by matrix-synthesizing osteoblasts during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum BSAP was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in BSAP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
Time frame: Baseline, Month 6, and once yearly up to 4 years
Base Study: Percent Change From Baseline in N-Terminal Propeptide of Type 1 Collagen (P1NP) After Log-Transformation
P1NP is a cleavage fragment produced during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum P1NP was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in P1NP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
Time frame: Baseline, Month 6, and once yearly up to 4 years
Base Study: Time to First 3-Point Major Adverse Cardiac Event (MACE) Confirmed by Thrombolysis in Myocardial Infarction Study Group (TIMI) Adjudication
The time to first TIMI-adjudicated 3-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, or 3. non-fatal definite stroke) was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First New Onset Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First 4-Point MACE Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated 4-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, 3. non-fatal definite stroke, or 4. hospitalization for unstable angina) was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First Hospitalization for Unstable Angina Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated hospitalization for unstable angina was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First New Onset ECG-Confirmed Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First Any Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated any reported episode of atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were included and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First All-Cause Death Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated all-cause death was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First Cardiovascular Death Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated cardiovascular death was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First Fatal or Non-Fatal Myocardial Infarction Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated fatal or non-fatal definite myocardial infarction was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First Fatal Myocardial Infarction Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated fatal definite myocardial infarction was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated fatal or non-fatal definite stroke was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study: Time to First Fatal Stroke Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated fatal definite stroke was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 60 months of observation
Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Femoral Neck
BMD was measured by DXA for all participants at the femoral neck-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp).
Time frame: Baseline, Month 6, and once yearly, up to approximately 74 months of observation
Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Distal-Third Forearm
BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study + first extension-dbp) in an approximate 10% random subset of participants at selected sites.
Time frame: Baseline and once yearly, up to approximately 74 months of observation
Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated)
Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Fracture (Adjudicated)
Osteoporotic clinical fractures (combining vertebral and non-vertebral) were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur or shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Total Hip
BMD was measured by DXA for all participants at the total hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp).
Time frame: Baseline, Month 6, and once yearly, up to approximately 74 months of observation
Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Trochanter
BMD was measured by DXA for all participants at the trochanter-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp).
Time frame: Baseline, Month 6, and once yearly, up to approximately 74 months of observation
Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Lumbar Spine
BMD was measured by DXA for all participants at the lumbar spine at randomization, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses.
Time frame: Baseline, Month 6, and once yearly, up to approximately 74 months of observation
Base Study + First Extension + Second Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture
Morphometric vertebral fractures were assessed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline (base study) and at Months 6, 12, and subsequent yearly time points. Incident fractures (i.e., occurring after baseline) in previously normal vertebral bodies and/or those occurring after baseline in previously fractured vertebral bodies (Genant semiquantitative \[SQ\] Grade 1-3) (T4 to L4) were confirmed by quantitative morphometric (QM) and either SQ or binary SQ (yes/no) methodologies. A time-to-event methodology was used to evaluate results: life-table estimates of the incidence proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and subsequent yearly intervals; an interval-censored approach was then used to determine incidence rate (number of participants with a morphometric fracture per 100 person-years of follow-up).
Time frame: Up to approximately 108 months of observation
Base Study + First Extension + Second Extension: Change in Height From Baseline Stature
Height was measured by wall-mounted stadiometer at randomization and at yearly intervals across the base study and the two extension studies.
Time frame: Baseline and once yearly, up to approximately 108 months of observation
Base Study + First Extension + Second Extension: Percent Change From Baseline in BMD Measurements of the Lumbar Spine
BMD was measured by DXA at the lumbar spine starting at randomization, and at yearly intervals until the end of the study (2nd extension study) for all participants who entered the 2nd extension study. Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses. At Months 96 and 108, approximately 3% or fewer participants in each treatment group had BMD data, and results at those time points should be viewed with caution. NOTE: The mean percent change in BMD from baseline in participants originally randomized to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in the base study. A longitudinal model with terms for treatment, stratum, region \& interaction between treatment and time as fixed effects (LS means weighted for region \& stratum size) was used for analysis.
Time frame: Baseline and once yearly, up to approximately 108 months of observation
Base Study + First Extension + Second Extension: Percent Change From Baseline in BMD Measurements of the Femoral Neck
BMD was measured by DXA at the femoral neck starting at screening, and at yearly intervals until the end of the study (2nd extension study) for all participants who entered the 2nd extension study. LS means percent change in BMD from original baseline are provided through Month 108. At Months 96 and 108, approximately 3% or fewer participants in each treatment group had BMD data, and results at those time points should be viewed with caution. NOTE: The mean percent change in BMD from baseline in participants originally randomized to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in the base study. A longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size) was used for analysis.
Time frame: Baseline and once yearly, up to approximately 108 months of observation
Base Study + First Extension + Second Extension: Percent Change From Baseline in BMD Measurements of the Trochanter
BMD was measured by DXA at the trochanter starting at screening, and at yearly intervals until the end of the study (2nd extension study) for all participants who entered the 2nd extension study. LS means percent change in BMD from original baseline are provided through Month 108. At Months 96 and 108, approximately 3% or fewer participants in each treatment group had BMD data, and results at those time points should be viewed with caution. NOTE: The mean percent change in BMD from baseline in participants originally randomized to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in the base study. A longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size) was used for analysis.
Time frame: Baseline and once yearly, up to approximately 108 months of observation
Second Extension: Incidence of Osteoporotic Clinical Lumbar Vertebral Fracture (Adjudicated)
Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all lumbar vertebral levels (L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence of participants in the second extension study with osteoporotic vertebral clinical fractures is provided. Due to early termination of the study, the cumulative incidence using a time-to-event methodology was not assessed across base and extension studies.
Time frame: Up to approximately 34 months of observation
Second Extension: Incidence of Osteoporotic Clinical Thoracic Vertebral Fracture (Adjudicated)
Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all thoracic vertebral levels (T1 to T12). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence of participants in the second extension study with osteoporotic vertebral clinical fractures is provided. Due to early termination of the study, the cumulative incidence using a time-to-event methodology was not assessed across base and extension studies.
Time frame: Up to approximately 34 months of observation
Second Extension: Time From Baseline to First Osteoporotic Clinical Fracture of Any Type (Adjudicated)
Osteoporotic clinical fractures of any type were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur or shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist; Vertebral fractures assessed across all vertebral levels (C7, T1 to T12, L1 to L5) were included in the analysis. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence proportion (cumulative incidence) of participants in the second extension study with at least one osteoporotic clinical fracture of any type is provided.
Time frame: Up to approximately 34 months of observation
Imaging Substudy PN032-Base: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography
Compartment-specific effects of osteoporosis were assessed by measuring cortical vBMD at the total hip using quantitative computed tomography. The percent change from baseline at Month 24 was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base: Percent Change From Baseline in Areal BMD (aBMD) of the Lumbar Spine Using DXA
aBMD was measured at the lumbar spine (L1 to L4) at baseline and Month 24 using DXA . If a vertebra was fractured at baseline or became fractured during the study, its BMD measurement was excluded from analysis. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA
aBMD was measured at the femoral neck at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Total Hip Using DXA
aBMD was measured at the total hip at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Trochanter Using DXA
aBMD was measured at the trochanter at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base: Percent Change From Baseline in s-CTx After Log-Transformation
s-CTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction from baseline in s-CTx was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base: Percent Change From Baseline in P1NP After Log-Transformation
P1NP is a cleavage fragment produced during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum P1NP was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction change from baseline in P1NP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Distal-Third Forearm Using DXA
aBMD was measured at the the distal one-third radius at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base: Percent Change From Baseline in BSAP After Log-Transformation
BSAP is an enzyme produced by matrix-synthesizing osteoblasts during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum BSAP was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction from baseline in BSAP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base: Percent Change From Baseline in u-NTx/Cr Ratio After Log-Transformation
u-NTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. Urine NTx measurements (in BCE) were normalized to urine Cr concentration (i.e., u-NTx/Cr ratio) and the log-transformed fraction from baseline in u-NTx/Cr ratio was then determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
Time frame: Baseline, Month 24
Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography
Compartment-specific effects of osteoporosis were assessed by measuring cortical vBMD at the total hip using quantitative computed tomography. The percent change from baseline at Month 60 (base study + extension study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 60
Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Lumbar Spine Using DXA
aBMD was measured at the lumbar spine (L1 to L4) at baseline and Month 60 using DXA . If a vertebra was fractured at baseline or became fractured during the study, its BMD measurement was excluded from analysis. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 60
Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Total Hip Using DXA
aBMD was measured at the total hip at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 60
Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA
aBMD was measured at the femoral neck at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 60
Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Trochanter Using DXA
aBMD was measured at the trochanter at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
Time frame: Baseline, Month 60
Base Study + First Extension: Time to First Hospitalization for Unstable Angina Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated hospitalization for unstable angina was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First Cardiovascular Death Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated cardiovascular death was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First Fatal Myocardial Infarction Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated fatal definite myocardial infarction was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First 3-Point MACE Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated 3-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, or 3. non-fatal definite stroke) was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First All-Cause Death Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated all-cause death was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First New Onset ECG-Confirmed Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First Fatal or Non-Fatal Myocardial Infarction Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated fatal or non-fatal definite myocardial infarction was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated fatal or non-fatal definite stroke was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First Any Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated any reported episode of atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were included and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First Fatal Stroke Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated fatal definite stroke was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First 4-Point MACE Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated 4-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, 3. non-fatal definite stroke, or 4. hospitalization for unstable angina) was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
Base Study + First Extension: Time to First New Onset Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication
The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
Time frame: Up to approximately 74 months of observation
| Milestone | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Started | 8043 | 8028 |
| Completed | 4297 | 3960 |
| Not completed | 3746 | 4068 |
| Withdrew: Adverse event | 525 | 470 |
| Withdrew: Lack of efficacy | 16 | 75 |
| Withdrew: Lost to follow-up | 221 | 208 |
| Withdrew: Other protocol specified criteria | 19 | 20 |
| Withdrew: Physician decision | 60 | 52 |
| Withdrew: Protocol violation | 48 | 38 |
| Withdrew: Withdrawal by subject | 1062 | 967 |
| Withdrew: Did not continue into extension | 1795 | 2238 |
| Milestone | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Started | 4297 | 3960 |
| Completed | 3144 | 2309 |
| Not completed | 1153 | 1651 |
| Withdrew: Adverse event | 162 | 142 |
| Withdrew: Lack of efficacy | 65 | 427 |
| Withdrew: Lost to follow-up | 41 | 37 |
| Withdrew: Other | 27 | 47 |
| Withdrew: Physician decision | 50 | 45 |
| Withdrew: Protocol violation | 16 | 13 |
| Withdrew: Withdrawal by subject | 296 | 287 |
| Withdrew: Disposition record non-existing | 0 | 1 |
| Withdrew: Discontinued after 5 years completion | 208 | 346 |
| Withdrew: Did not cont. into 2nd ext (verified) | 256 | 281 |
| Withdrew: Did not cont. into 2nd ext (unknown) | 32 | 25 |
| Milestone | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Started | 3144 | 2309 |
| Completed | 2844 | 2112 |
| Not completed | 300 | 197 |
| Withdrew: Adverse event | 101 | 51 |
| Withdrew: Lack of efficacy | 7 | 15 |
| Withdrew: Lost to follow-up | 18 | 12 |
| Withdrew: Other | 7 | 12 |
| Withdrew: Physician decision | 63 | 26 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 97 | 75 |
| Withdrew: Status missing | 5 | 5 |
Morphometric vertebral fractures were assessed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline and at Months 6, 12, and subsequent yearly time points. Incident fractures (i.e., occurring after baseline) in previously normal vertebral bodies and/or those occurring after baseline in previously fractured vertebral bodies (Genant semiquantitative \[SQ\] Grade 1-3) (T4 to L4) were confirmed by quantitative morphometric (QM) and either SQ or binary SQ (yes/no) methodologies. A time-to-event methodology was used to evaluate results: life-table estimates of the incidence proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and subsequent yearly intervals; an interval-censored approach was then used to determine incidence rate (number of participants with a morphometric fracture per 100 person-years of follow-up).
| Parts. w/ fracture per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture | 1.27 | 2.74 |
Osteoporotic clinical hip fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Hip fractures were fractures of the proximal femur confirmed as being located in the hip (i.e., sub-region not specified; cervical, and intertrochanteric). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
| Parts. w/ fracture per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated) | 0.28 | 0.54 |
Osteoporotic non-vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur or shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
| Parts. w/ fracture per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated) | 1.85 | 2.41 |
Morphometric vertebral fractures were confirmed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline and at Months 6, 12, and subsequent yearly time points. Incident fractures (i.e., occurring after baseline) in previously normal vertebral bodies and/or those occurring after baseline in previously fractured vertebral bodies (Genant SQ Grade 1-3) (T4 to L4) were confirmed by QM and either SQ or binary SQ (yes/no) methodologies. A time-to-event methodology was used to evaluate results: life-table estimates of the incidence proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and subsequent yearly intervals; an interval-censored approach was then used to determine incidence rate (number of participants with a morphometric fracture per 100 person-years of follow-up).
| Parts. w/ fracture per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture | 1.33 | 2.74 |
Osteoporotic clinical hip fractures was confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Hip fractures were fractures of the proximal femur confirmed as being located in the hip (i.e., sub-region not specified; cervical, and intertrochanteric). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
| Parts. w/ fracture per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated) | 0.29 | 0.56 |
Osteoporotic non-vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur and shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
| Parts. w/ fracture per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated) | 1.78 | 2.41 |
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participants with adverse events (number of participants with an event per 100 person-years of follow-up) is provided.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Rate of Adverse Events | 97.25 (95.00 to 99.53) | 96.36 (94.13 to 98.63) |
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participant discontinuations from treatment due to adverse events (number of participants with an event per 100 person-years of follow-up) is provided.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Rate of Discontinuations From Study Treatment Due to an Adverse Event | 2.66 (2.48 to 2.86) | 2.55 (2.37 to 2.75) |
BMD was measured by dual-energy x-ray absorptiometry (DXA) at the total hip starting at screening, and at yearly intervals until the end of the study (second extension study) for all participants who entered the second extension study. Least squares (LS) means percent change in BMD from original baseline are provided through Month 108 (Year 9). At Months 96 (Year 8) and 108 (Year 9), approximately 3% or fewer participants in each treatment group had BMD data, and results at those time points should be viewed with caution. NOTE: The mean percent change in BMD from baseline in participants originally randomized to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in the base study.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 12 | 3.03 (2.91 to 3.14) | 1.08 (0.95 to 1.22) |
| Month 24 | 4.32 (4.18 to 4.46) | 0.58 (0.42 to 0.74) |
| Month 36 | 5.60 (5.43 to 5.77) | 0.04 (-0.16 to 0.24) |
| Month 48 | 6.56 (6.36 to 6.76) | -0.74 (-0.97 to -0.51) |
| Month 60 | 7.45 (7.22 to 7.68) | -1.40 (-1.67 to -1.13) |
| Month 72 | 7.88 (7.62 to 8.14) | -0.01 (-0.31 to 0.30) |
| Month 84 | 7.94 (7.63 to 8.26) | 0.97 (0.61 to 1.34) |
| Month 96 | 7.87 (7.38 to 8.37) | 1.57 (1.01 to 2.13) |
| Month 108 | 7.03 (6.02 to 8.05) | 1.11 (-0.02 to 2.23) |
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Participants | Odanacatib 50 mg OW | Placebo (Originally Assigned to Placebo) |
|---|---|---|
| Second Extension: Number of Participants Who Experienced an Adverse Event | 2173 | 1587 |
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
| Participants | Odanacatib 50 mg OW | Placebo (Originally Assigned to Placebo) |
|---|---|---|
| Second Extension: Number of Participants Discontinuing Study Treatment Due to an Adverse Event | 55 | 36 |
Compartment-specific effects of osteoporosis were assessed by measuring trabecular vBMD at the lumbar spine (L1 total vertebral body) using quantitative computed tomography. The percent change from baseline at Month 24 (base study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in Volumetric Bone Mineral Density (vBMD) at the Lumbar Spine Using Quantitative Computed Tomography | 8.05 (4.48 to 11.62) | -0.87 (-4.37 to 2.64) |
Compartment-specific effects of osteoporosis were assessed by measuring trabecular vBMD at the lumbar spine (L1 total vertebral body) using quantitative computed tomography. The percent change from baseline at Month 60 (base study + extension study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in vBMD at the Lumbar Spine Using Quantitative Computed Tomography | 14.76 (7.68 to 21.83) | -11.69 (-18.69 to -4.69) |
Sarcopenia is the age-related loss of skeletal muscle mass and associated loss of strength. Progression of sarcopenia was assessed using aLBM as measured by total body DXA. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| kg | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 12 | -0.20 (-0.28 to -0.12) | -0.18 (-0.26 to -0.10) |
| Month 24 | -0.19 (-0.28 to -0.10) | -0.19 (-0.28 to -0.10) |
| Month 36 | -0.36 (-0.45 to -0.27) | -0.32 (-0.41 to -0.23) |
| Month 48 | -0.44 (-0.64 to -0.24) | -0.23 (-0.44 to -0.02) |
The Short Physical Performance Battery (SPPB) Score is used to assess physical function in older persons. The SPPB consists of 3 types of physical activities: standing balance, gait speed, and chair rise. Component activities are timed and then reduced to a categorical 0 to 4 scale based on time achieved. A higher composite score (range 0 to 12) indicates an improved function level. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Score on a scale | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 12 | 0.03 (-0.16 to 0.22) | -0.08 (-0.27 to 0.11) |
| Month 24 | -0.04 (-0.25 to 0.16) | -0.19 (-0.40 to 0.02) |
| Month 36 | -0.18 (-0.42 to 0.06) | -0.37 (-0.62 to -0.13) |
| Month 48 | -0.05 (-0.34 to 0.24) | -0.24 (-0.55 to 0.07) |
Gait speed is a component of the Short Physical Performance Battery (SPPB) Score. Participants are asked to walk a distance of 4 meters at their normal pace. The test is performed 2 times, and the walk done in the shortest time is used for scoring. The activity is timed and then reduced to a categorical 0 to 4 scale based on time achieved. Higher scores indicate an improved function level. The change from baseline at yearly intervals was then assessed using a longitudinal data analysis model with terms for treatment, stratum (sarcopenia, non-sarcopenia), time and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Score on a scale | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 12 | -0.02 (-0.10 to 0.06) | -0.06 (-0.14 to 0.02) |
| Month 24 | -0.02 (-0.11 to 0.07) | -0.10 (-0.19 to -0.00) |
| Month 36 | -0.09 (-0.19 to 0.02) | -0.11 (-0.22 to -0.01) |
| Month 48 | -0.15 (-0.28 to -0.02) | -0.24 (-0.38 to -0.10) |
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participants with adverse events (number of participants with an event per 100 person-years of follow-up) is provided.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Rate of Adverse Events | 100.16 (97.81 to 102.6) | 98.65 (96.33 to 101.01) |
An adverse event is defined as any untoward medical occurrence in a person or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The incidence rate of participant discontinuations from treatment due to adverse events (number of participants with an event per 100 person-years of follow-up) is provided.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Rate of Discontinuation From Study Treatment Due to an Adverse Event | 2.97 (2.75 to 3.20) | 2.70 (2.49 to 2.92) |
Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
| Parts. w/ fracture per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated) | 0.16 | 0.58 |
Height was measured by wall-mounted stadiometer at randomization and at yearly intervals in the base study.
| cm/year | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Yearly Rate of Height Loss | -0.13 (-0.14 to -0.12) | -0.15 (-0.16 to -0.14) |
Height was measured by wall-mounted stadiometer at randomization and at yearly intervals in the base study.
| Participants | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Up to Month 12 | 316 | 365 |
| Up to Month 24 | 592 | 669 |
| Up to Month 36 | 875 | 944 |
| Up to Month 48 | 90 | 59 |
| Up to Month 60 | 23 | 12 |
| Overall/At any time | 1022 | 1149 |
BMD was measured by DXA for all participants at the total hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | 1.85 (1.54 to 2.16) | 0.53 (0.24 to 0.81) |
| Month 12 | 2.82 (2.74 to 2.91) | 0.33 (0.25 to 0.42) |
| Month 24 | 3.79 (3.68 to 3.90) | -0.68 (-0.79 to -0.57) |
| Month 36 | 4.81 (4.67 to 4.94) | -1.64 (-1.78 to -1.50) |
| Month 48 | 5.39 (5.04 to 5.74) | -3.23 (-3.59 to -2.87) |
| Month 60 | 5.67 (5.13 to 6.21) | -3.82 (-4.40 to -3.24) |
BMD was measured by DXA for all participants at the lumbar spine at randomization, Months 6, 12, and subsequent yearly intervals until the end of the study (base study). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses. at
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | 3.75 (3.39 to 4.11) | 0.78 (0.44 to 1.13) |
| Month 12 | 4.67 (4.56 to 4.77) | 0.59 (0.49 to 0.70) |
| Month 24 | 6.77 (6.64 to 6.90) | 0.72 (0.59 to 0.84) |
| Month 36 | 8.59 (8.43 to 8.74) | 0.75 (0.59 to 0.90) |
| Month 48 | 10.47 (10.09 to 10.86) | 0.76 (0.35 to 1.16) |
| Month 60 | 11.49 (10.82 to 12.17) | 0.26 (-0.47 to 1.00) |
BMD was measured by DXA for all participants at the femoral neck-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | 2.17 (1.78 to 2.55) | 0.68 (0.30 to 1.06) |
| Month 12 | 2.80 (2.68 to 2.91) | 0.59 (0.48 to 0.70) |
| Month 24 | 4.01 (3.88 to 4.15) | -0.37 (-0.50 to -0.23) |
| Month 36 | 5.45 (5.29 to 5.61) | -1.01 (-1.17 to -0.85) |
| Month 48 | 6.15 (5.74 to 6.56) | -2.27 (-2.71 to -1.83) |
| Month 60 | 6.69 (6.02 to 7.36) | -1.84 (-2.58 to -1.11) |
BMD was measured by DXA for all participants at the trochanter-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | 2.65 (2.12 to 3.18) | 0.91 (0.43 to 1.38) |
| Month 12 | 4.32 (4.18 to 4.46) | 0.82 (0.68 to 0.96) |
| Month 24 | 6.17 (6.00 to 6.34) | -0.24 (-0.41 to -0.07) |
| Month 36 | 8.01 (7.81 to 8.22) | -1.26 (-1.47 to -1.05) |
| Month 48 | 9.46 (8.92 to 10.00) | -2.98 (-3.54 to -2.42) |
| Month 60 | 10.16 (9.32 to 10.99) | -3.65 (-4.55 to -2.75) |
BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study) in an approximate 10% random subset of participants at selected sites.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 12 | 0.51 (0.19 to 0.82) | -0.60 (-0.91 to -0.30) |
| Month 24 | 0.33 (-0.03 to 0.68) | -1.02 (-1.37 to -0.68) |
| Month 36 | 0.02 (-0.36 to 0.41) | -1.90 (-2.29 to -1.52) |
| Month 48 | -0.62 (-1.52 to 0.28) | -2.82 (-3.76 to -1.88) |
| Month 60 | 0.29 (-1.08 to 1.66) | -3.21 (-4.72 to -1.70) |
BMD was measured by DXA in bisphosphonate-intolerant participants at the lumbar spine at randomization, and at yearly intervals until the end of the study (base study). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses. Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | NA (NA to NA) | NA (NA to NA) |
| Month 12 | 4.56 (4.31 to 4.80) | 0.54 (0.29 to 0.78) |
| Month 24 | 6.60 (6.31 to 6.90) | 0.82 (0.52 to 1.11) |
| Month 36 | 8.49 (8.13 to 8.85) | 0.87 (0.50 to 1.23) |
| Month 48 | 10.31 (9.34 to 11.29) | 0.80 (-0.40 to 2.00) |
| Month 60 | NA (NA to NA) | NA (NA to NA) |
BMD was measured by DXA in bisphosphonate-intolerant participants at the total hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | NA (NA to NA) | NA (NA to NA) |
| Month 12 | 2.63 (2.43 to 2.83) | 0.24 (0.04 to 0.44) |
| Month 24 | 3.56 (3.30 to 3.82) | -0.64 (-0.90 to -0.39) |
| Month 36 | 4.45 (4.14 to 4.76) | -1.41 (-1.72 to -1.09) |
| Month 48 | 4.07 (3.09 to 5.04) | -4.47 (-5.67 to -3.27) |
| Month 60 | NA (NA to NA) | NA (NA to NA) |
BMD was measured by DXA in bisphosphonate-intolerant participants at the femoral neck-hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | NA (NA to NA) | NA (NA to NA) |
| Month 12 | 2.71 (2.44 to 2.98) | 0.50 (0.24 to 0.77) |
| Month 24 | 3.88 (3.56 to 4.19) | -0.45 (-0.77 to -0.13) |
| Month 36 | 5.12 (4.75 to 5.50) | -0.97 (-1.35 to -0.59) |
| Month 48 | 6.75 (5.43 to 8.08) | -2.32 (-3.96 to -0.68) |
| Month 60 | NA (NA to NA) | NA (NA to NA) |
BMD was measured by DXA in bisphosphonate-intolerant participants at the trochanter-hip at screening, and at yearly intervals until the end of the study (base study). Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | NA (NA to NA) | NA (NA to NA) |
| Month 12 | 4.02 (3.70 to 4.35) | 0.58 (0.26 to 0.90) |
| Month 24 | 5.73 (5.33 to 6.12) | -0.30 (-0.70 to 0.10) |
| Month 36 | 7.47 (6.99 to 7.94) | -1.02 (-1.50 to -0.54) |
| Month 48 | 6.68 (5.04 to 8.32) | -5.07 (-7.09 to -3.05) |
| Month 60 | NA (NA to NA) | NA (NA to NA) |
BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study) in an approximate 10% random subset of bisphosphonate-intolerant participants at selected sites. Bisphosphonates are anti-resorptive agents used in the treatment of osteoporosis. Bisphosphonate-intolerance was defined by contraindication or history of intolerance to bisphosphonates, or physician's determination of unsuitability for bisphosphonate treatment.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 12 | 0.99 (0.06 to 1.93) | -0.09 (-0.87 to 0.69) |
| Month 24 | 0.24 (-0.79 to 1.28) | -0.80 (-1.67 to 0.06) |
| Month 36 | -0.66 (-1.76 to 0.44) | -1.87 (-2.82 to -0.92) |
| Month 48 | -0.72 (-4.90 to 3.45) | -2.27 (-7.23 to 2.68) |
| Month 60 | — | NA (NA to NA) |
s-CTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in s-CTx was determined using a longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | -61.27 (-63.33 to -59.09) | -2.28 (-7.43 to 3.15) |
| Month 12 | -53.47 (-55.98 to -50.81) | 6.54 (0.85 to 12.56) |
| Month 24 | -39.47 (-42.61 to -36.15) | 7.23 (1.70 to 13.07) |
| Month 36 | -23.71 (-27.79 to -19.40) | 20.96 (14.38 to 27.91) |
| Month 48 | -4.61 (-15.93 to 8.24) | 14.12 (0.47 to 29.61) |
u-NTx, a biochemical marker of bone resorption, was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. Urine NTx measurements (in bone collagen equivalents \[BCE\]) were normalized to urine Cr concentration (i.e., u-NTx/Cr ratio) and the log-transformed fraction from baseline in u-NTx/Cr ratio was then determined using a longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | -56.46 (-58.27 to -54.56) | -4.76 (-8.68 to -0.67) |
| Month 12 | -55.58 (-57.54 to -53.53) | -1.99 (-6.26 to 2.48) |
| Month 24 | -47.21 (-49.70 to -44.61) | 9.46 (4.33 to 14.85) |
| Month 36 | -43.91 (-46.80 to -40.86) | 15.23 (9.15 to 21.64) |
| Month 48 | -38.01 (-46.30 to -28.43) | 6.53 (-7.38 to 22.53) |
BSAP is an enzyme produced by matrix-synthesizing osteoblasts during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum BSAP was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in BSAP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | -23.27 (-25.12 to -21.38) | -9.13 (-11.28 to -6.93) |
| Month 12 | -21.43 (-23.53 to -19.27) | -9.42 (-11.80 to -6.97) |
| Month 24 | -9.33 (-12.10 to -6.47) | -0.04 (-3.07 to 3.08) |
| Month 36 | -8.41 (-11.23 to -5.51) | -0.77 (-3.85 to 2.40) |
| Month 48 | -0.63 (-8.39 to 7.80) | 0.15 (-7.93 to 8.94) |
P1NP is a cleavage fragment produced during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum P1NP was assessed at randomization, Month 6, and at yearly intervals until the end of the study (base study) in an approximate 10% random subset participants at selected sites. The log-transformed fraction from baseline in P1NP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | -44.51 (-46.71 to -42.23) | -15.08 (-18.39 to -11.65) |
| Month 12 | -37.49 (-40.12 to -34.75) | -11.55 (-15.21 to -7.72) |
| Month 24 | -22.46 (-25.69 to -19.09) | -6.20 (-10.08 to -2.16) |
| Month 36 | -11.89 (-15.70 to -7.92) | 0.22 (-4.15 to 4.78) |
| Month 48 | -3.61 (-12.04 to 5.62) | -0.28 (-9.25 to 9.58) |
The time to first TIMI-adjudicated 3-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, or 3. non-fatal definite stroke) was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First 3-Point Major Adverse Cardiac Event (MACE) Confirmed by Thrombolysis in Myocardial Infarction Study Group (TIMI) Adjudication | 1.17 | 1.04 |
The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First New Onset Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication | 0.48 | 0.41 |
The time to first TIMI-adjudicated 4-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, 3. non-fatal definite stroke, or 4. hospitalization for unstable angina) was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First 4-Point MACE Confirmed by TIMI Adjudication | 1.28 | 1.14 |
The time to first TIMI-adjudicated hospitalization for unstable angina was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First Hospitalization for Unstable Angina Confirmed by TIMI Adjudication | 0.10 | 0.09 |
The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First New Onset ECG-Confirmed Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication | 0.25 | 0.23 |
The time to first TIMI-adjudicated any reported episode of atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were included and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First Any Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication | 0.60 | 0.48 |
The time to first TIMI-adjudicated all-cause death was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First All-Cause Death Confirmed by TIMI Adjudication | 1.55 | 1.38 |
The time to first TIMI-adjudicated cardiovascular death was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First Cardiovascular Death Confirmed by TIMI Adjudication | 0.45 | 0.39 |
The time to first TIMI-adjudicated fatal or non-fatal definite myocardial infarction was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First Fatal or Non-Fatal Myocardial Infarction Confirmed by TIMI Adjudication | 0.25 | 0.31 |
The time to first TIMI-adjudicated fatal definite myocardial infarction was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First Fatal Myocardial Infarction Confirmed by TIMI Adjudication | 0.03 | 0.03 |
The time to first TIMI-adjudicated fatal or non-fatal definite stroke was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication | 0.58 | 0.44 |
The time to first TIMI-adjudicated fatal definite stroke was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Time to First Fatal Stroke Confirmed by TIMI Adjudication | 0.09 | 0.05 |
BMD was measured by DXA for all participants at the femoral neck-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | 2.17 (1.78 to 2.55) | 0.70 (0.32 to 1.08) |
| Month 12 | 2.81 (2.70 to 2.92) | 0.60 (0.49 to 0.71) |
| Month 24 | 4.03 (3.90 to 4.16) | -0.36 (-0.49 to -0.22) |
| Month 36 | 5.48 (5.32 to 5.64) | -1.02 (-1.18 to -0.86) |
| Month 48 | 6.37 (6.17 to 6.56) | -1.93 (-2.13 to -1.73) |
| Month 60 | 7.30 (7.08 to 7.53) | -2.75 (-2.99 to -2.51) |
BMD was measured by DXA at the distal one-third radius at randomization and at yearly intervals until the end of the study (base study + first extension-dbp) in an approximate 10% random subset of participants at selected sites.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 12 | 0.50 (0.18 to 0.81) | -0.61 (-0.91 to -0.30) |
| Month 24 | 0.33 (-0.01 to 0.68) | -1.02 (-1.37 to -0.68) |
| Month 36 | 0.05 (-0.33 to 0.43) | -1.91 (-2.29 to -1.53) |
| Month 48 | -0.30 (-0.84 to 0.23) | -2.49 (-3.05 to -1.92) |
| Month 60 | -0.84 (-1.37 to -0.31) | -3.17 (-3.74 to -2.59) |
Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated) | 0.18 | 0.56 |
Osteoporotic clinical fractures (combining vertebral and non-vertebral) were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all vertebral levels (C7, T1 to T12, L1 to L5). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur or shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence rate of participants with fracture (number of participants with a fracture per 100 person-years of follow-up) is provided.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Fracture (Adjudicated) | 1.95 | 2.93 |
BMD was measured by DXA for all participants at the total hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | 1.89 (1.60 to 2.17) | 0.55 (0.26 to 0.83) |
| Month 12 | 2.84 (2.75 to 2.92) | 0.34 (0.26 to 0.43) |
| Month 24 | 3.79 (3.68 to 3.90) | -0.67 (-0.78 to -0.57) |
| Month 36 | 4.78 (4.65 to 4.92) | -1.67 (-1.81 to -1.54) |
| Month 48 | 5.52 (5.35 to 5.69) | -2.97 (-3.14 to -2.79) |
| Month 60 | 6.23 (6.02 to 6.44) | -4.06 (-4.28 to -3.84) |
BMD was measured by DXA for all participants at the trochanter-hip at screening, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | 2.70 (2.21 to 3.18) | 0.95 (0.47 to 1.43) |
| Month 12 | 4.33 (4.19 to 4.47) | 0.83 (0.69 to 0.97) |
| Month 24 | 6.17 (6.00 to 6.34) | -0.23 (-0.40 to -0.06) |
| Month 36 | 7.96 (7.75 to 8.16) | -1.29 (-1.50 to -1.08) |
| Month 48 | 9.27 (9.01 to 9.53) | -2.86 (-3.13 to -2.59) |
| Month 60 | 10.66 (10.36 to 10.97) | -3.90 (-4.22 to -3.57) |
BMD was measured by DXA for all participants at the lumbar spine at randomization, Months 6, 12, and subsequent yearly intervals until the end of the study (base study + first extension-dbp). Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 6 | 3.72 (3.36 to 4.07) | 0.82 (0.47 to 1.17) |
| Month 12 | 4.61 (4.50 to 4.71) | 0.60 (0.49 to 0.70) |
| Month 24 | 6.63 (6.50 to 6.76) | 0.70 (0.58 to 0.83) |
| Month 36 | 8.41 (8.26 to 8.56) | 0.72 (0.56 to 0.87) |
| Month 48 | 10.19 (10.01 to 10.38) | 0.85 (0.66 to 1.04) |
| Month 60 | 11.93 (11.71 to 12.15) | 1.06 (0.83 to 1.29) |
Morphometric vertebral fractures were assessed by central adjudication on lumbar and thoracic spinal radiographs acquired at baseline (base study) and at Months 6, 12, and subsequent yearly time points. Incident fractures (i.e., occurring after baseline) in previously normal vertebral bodies and/or those occurring after baseline in previously fractured vertebral bodies (Genant semiquantitative \[SQ\] Grade 1-3) (T4 to L4) were confirmed by quantitative morphometric (QM) and either SQ or binary SQ (yes/no) methodologies. A time-to-event methodology was used to evaluate results: life-table estimates of the incidence proportion (cumulative incidence) of participants with at least one morphometric vertebral fracture were assessed at Months 6, 12, and subsequent yearly intervals; an interval-censored approach was then used to determine incidence rate (number of participants with a morphometric fracture per 100 person-years of follow-up).
No measurements were reported for this outcome.
Height was measured by wall-mounted stadiometer at randomization and at yearly intervals across the base study and the two extension studies.
No measurements were reported for this outcome.
BMD was measured by DXA at the lumbar spine starting at randomization, and at yearly intervals until the end of the study (2nd extension study) for all participants who entered the 2nd extension study. Measurements were made on at least 3 vertebrae for all time points; vertebrae with fractures were excluded from analyses. At Months 96 and 108, approximately 3% or fewer participants in each treatment group had BMD data, and results at those time points should be viewed with caution. NOTE: The mean percent change in BMD from baseline in participants originally randomized to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in the base study. A longitudinal model with terms for treatment, stratum, region \& interaction between treatment and time as fixed effects (LS means weighted for region \& stratum size) was used for analysis.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 12 | 4.68 (4.54 to 4.83) | 1.01 (0.84 to 1.17) |
| Month 24 | 6.95 (6.78 to 7.12) | 1.40 (1.21 to 1.59) |
| Month 36 | 8.84 (8.65 to 9.04) | 1.61 (1.39 to 1.83) |
| Month 48 | 10.74 (10.51 to 10.97) | 2.06 (1.80 to 2.33) |
| Month 60 | 12.55 (12.29 to 12.81) | 2.45 (2.16 to 2.75) |
| Month 72 | 13.76 (13.46 to 14.06) | 6.25 (5.91 to 6.59) |
| Month 84 | 14.91 (14.56 to 15.26) | 8.37 (7.97 to 8.77) |
| Month 96 | 15.13 (14.48 to 15.78) | 9.66 (8.95 to 10.38) |
| Month 108 | 15.54 (14.23 to 26.85) | 10.85 (9.42 to 12.27) |
BMD was measured by DXA at the femoral neck starting at screening, and at yearly intervals until the end of the study (2nd extension study) for all participants who entered the 2nd extension study. LS means percent change in BMD from original baseline are provided through Month 108. At Months 96 and 108, approximately 3% or fewer participants in each treatment group had BMD data, and results at those time points should be viewed with caution. NOTE: The mean percent change in BMD from baseline in participants originally randomized to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in the base study. A longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size) was used for analysis.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 12 | 2.89 (2.73 to 3.05) | 1.06 (0.88 to 1.24) |
| Month 24 | 4.39 (4.20 to 4.57) | 0.38 (0.17 to 0.60) |
| Month 36 | 6.02 (5.81 to 6.24) | -0.03 (-0.28 to 0.22) |
| Month 48 | 7.01 (6.78 to 7.25) | -0.73 (-1.01 to -0.46) |
| Month 60 | 7.98 (7.70 to 8.25) | -1.32 (-1.63 to -1.00) |
| Month 72 | 8.51 (8.21 to 8.81) | 0.41 (0.06 to 0.76) |
| Month 84 | 9.11 (8.75 to 9.48) | 1.56 (1.13 to 1.98) |
| Month 96 | 8.84 (8.22 to 9.46) | 1.95 (1.24 to 2.65) |
| Month 108 | 9.38 (7.83 to 10.92) | 3.63 (1.91 to 5.35) |
BMD was measured by DXA at the trochanter starting at screening, and at yearly intervals until the end of the study (2nd extension study) for all participants who entered the 2nd extension study. LS means percent change in BMD from original baseline are provided through Month 108. At Months 96 and 108, approximately 3% or fewer participants in each treatment group had BMD data, and results at those time points should be viewed with caution. NOTE: The mean percent change in BMD from baseline in participants originally randomized to placebo includes BMD results obtained after those participants were switched to open-label odanacatib, which occurred at different times relative to their start of blinded study medication in the base study. A longitudinal model with terms for treatment, stratum, region and interaction between treatment and time as fixed effects (LS means weighted for region and stratum size) was used for analysis.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Month 12 | 4.55 (4.34 to 4.75) | 1.81 (1.58 to 2.05) |
| Month 24 | 6.85 (6.62 to 7.08) | 1.45 (1.18 to 1.72) |
| Month 36 | 9.00 (8.73 to 9.28) | 0.89 (0.57 to 1.21) |
| Month 48 | 10.58 (10.26 to 10.89) | -0.16 (-0.52 to 0.21) |
| Month 60 | 12.21 (11.85 to 12.57) | -0.68 (-1.09 to -0.26) |
| Month 72 | 12.95 (12.55 to 13.34) | 1.22 (0.76 to 1.68) |
| Month 84 | 13.30 (12.82 to 13.78) | 3.17 (2.61 to 3.73) |
| Month 96 | 13.44 (12.67 to 14.20) | 4.66 (3.79 to 5.54) |
| Month 108 | 12.69 (10.86 to 14.51) | 2.97 (0.95 to 5.00) |
Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all lumbar vertebral levels (L1 to L5). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence of participants in the second extension study with osteoporotic vertebral clinical fractures is provided. Due to early termination of the study, the cumulative incidence using a time-to-event methodology was not assessed across base and extension studies.
| Percentage of Participants | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Second Extension: Incidence of Osteoporotic Clinical Lumbar Vertebral Fracture (Adjudicated) | 0.22 | 0.04 |
Osteoporotic vertebral clinical fractures were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Vertebral fractures were assessed for all thoracic vertebral levels (T1 to T12). Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence of participants in the second extension study with osteoporotic vertebral clinical fractures is provided. Due to early termination of the study, the cumulative incidence using a time-to-event methodology was not assessed across base and extension studies.
| Percentage of Participants | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Second Extension: Incidence of Osteoporotic Clinical Thoracic Vertebral Fracture (Adjudicated) | 0.13 | 0.09 |
Osteoporotic clinical fractures of any type were confirmed by central adjudication using radiographic evidence on all symptomatic fractures reported as adverse experiences (excluding fractures of the fingers, toes, face, and skull). Non-vertebral fractures were assessed across multiple anatomical sites including clavicle, distal femur or shaft, fibula, hip, humerus, pelvis, radius, ribs, sacrum, tibia, ulna, and wrist; Vertebral fractures assessed across all vertebral levels (C7, T1 to T12, L1 to L5) were included in the analysis. Osteoporotic (fragility) fractures did not include fractures with traumatic or pathological etiologies. A clinical fracture was defined as a fracture with clinical fracture-related symptoms (e.g., pain). A time-to-event methodology was used to evaluate results: the incidence proportion (cumulative incidence) of participants in the second extension study with at least one osteoporotic clinical fracture of any type is provided.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Second Extension: Time From Baseline to First Osteoporotic Clinical Fracture of Any Type (Adjudicated) | 2.04 | 2.64 |
Compartment-specific effects of osteoporosis were assessed by measuring cortical vBMD at the total hip using quantitative computed tomography. The percent change from baseline at Month 24 was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography | 3.29 (2.33 to 4.24) | 0.52 (-0.39 to 1.44) |
aBMD was measured at the lumbar spine (L1 to L4) at baseline and Month 24 using DXA . If a vertebra was fractured at baseline or became fractured during the study, its BMD measurement was excluded from analysis. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in Areal BMD (aBMD) of the Lumbar Spine Using DXA | 5.63 (4.54 to 6.72) | 0.08 (-0.92 to 1.09) |
aBMD was measured at the femoral neck at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA | 3.15 (1.74 to 4.56) | 0.36 (-0.94 to 1.65) |
aBMD was measured at the total hip at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Total Hip Using DXA | 2.96 (2.03 to 3.90) | -0.66 (-1.52 to 0.20) |
aBMD was measured at the trochanter at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Trochanter Using DXA | 5.10 (3.74 to 6.45) | -0.55 (-1.80 to 0.70) |
s-CTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction from baseline in s-CTx was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in s-CTx After Log-Transformation | -55.62 (-62.53 to -47.44) | 6.62 (-8.51 to 24.26) |
P1NP is a cleavage fragment produced during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum P1NP was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction change from baseline in P1NP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in P1NP After Log-Transformation | -33.56 (-42.66 to -23.01) | -6.86 (-18.71 to 6.72) |
aBMD was measured at the the distal one-third radius at baseline and Month 24 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Distal-Third Forearm Using DXA | 0.40 (-0.57 to 1.36) | -1.27 (-2.18 to -0.36) |
BSAP is an enzyme produced by matrix-synthesizing osteoblasts during the synthesis of collagenous bone matrix (type 1 collagen) used as a biochemical marker of bone formation. Serum BSAP was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. The log-transformed fraction from baseline in BSAP was determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in BSAP After Log-Transformation | -12.39 (-19.20 to -4.99) | 12.64 (4.53 to 21.38) |
u-NTx, a biochemical marker of bone resorption by osteoclasts reflecting collagen breakdown products, was assessed at baseline and Month 24 in an approximate 10% random subset participants at selected sites in the P018 base study who were additionally included in the imaging substudy PN032-base study. Urine NTx measurements (in BCE) were normalized to urine Cr concentration (i.e., u-NTx/Cr ratio) and the log-transformed fraction from baseline in u-NTx/Cr ratio was then determined using a longitudinal model with terms for treatment, stratum, and interaction between treatment and time as fixed effects (LS means weighted for stratum size). Back-transformed weighted geometric LS means values for percent change from baseline are provided.
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base: Percent Change From Baseline in u-NTx/Cr Ratio After Log-Transformation | -47.87 (-57.26 to -36.42) | 16.56 (-2.85 to 39.84) |
Compartment-specific effects of osteoporosis were assessed by measuring cortical vBMD at the total hip using quantitative computed tomography. The percent change from baseline at Month 60 (base study + extension study) was then assessed using a longitudinal data analysis model including terms for treatment, stratum (prior vertebral fracture \[yes/no\]) and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography | 6.00 (4.07 to 7.93) | -2.53 (-4.48 to -0.59) |
aBMD was measured at the lumbar spine (L1 to L4) at baseline and Month 60 using DXA . If a vertebra was fractured at baseline or became fractured during the study, its BMD measurement was excluded from analysis. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Lumbar Spine Using DXA | 11.80 (9.86 to 13.73) | 0.72 (-1.10 to 2.54) |
aBMD was measured at the total hip at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Total Hip Using DXA | 5.34 (3.66 to 7.01) | -5.07 (-6.74 to -3.41) |
aBMD was measured at the femoral neck at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA | 6.87 (4.68 to 9.06) | -3.11 (-5.26 to -0.96) |
aBMD was measured at the trochanter at baseline and Month 60 using DXA. The percent change from baseline was assessed using a longitudinal data analysis model including terms for treatment, stratum and interaction between treatment and time as fixed effects (LS means weighted for stratum size).
| Percent change | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Trochanter Using DXA | 10.44 (7.84 to 13.03) | -4.50 (-7.07 to -1.94) |
The time to first TIMI-adjudicated hospitalization for unstable angina was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First Hospitalization for Unstable Angina Confirmed by TIMI Adjudication | 0.08 | 0.10 |
The time to first TIMI-adjudicated cardiovascular death was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First Cardiovascular Death Confirmed by TIMI Adjudication | 0.48 | 0.43 |
The time to first TIMI-adjudicated fatal definite myocardial infarction was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First Fatal Myocardial Infarction Confirmed by TIMI Adjudication | 0.02 | 0.03 |
The time to first TIMI-adjudicated 3-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, or 3. non-fatal definite stroke) was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First 3-Point MACE Confirmed by TIMI Adjudication | 1.24 | 1.06 |
The time to first TIMI-adjudicated all-cause death was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. The analysis includes data obtained from vital status data collections of participants no longer followed in the base study. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First All-Cause Death Confirmed by TIMI Adjudication | 1.79 | 1.70 |
The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First New Onset ECG-Confirmed Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication | 0.27 | 0.22 |
The time to first TIMI-adjudicated fatal or non-fatal definite myocardial infarction was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First Fatal or Non-Fatal Myocardial Infarction Confirmed by TIMI Adjudication | 0.26 | 0.28 |
The time to first TIMI-adjudicated fatal or non-fatal definite stroke was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication | 0.58 | 0.42 |
The time to first TIMI-adjudicated any reported episode of atrial fibrillation or atrial flutter was determined for the base study using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were included and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First Any Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication | 0.61 | 0.50 |
The time to first TIMI-adjudicated fatal definite stroke was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First Fatal Stroke Confirmed by TIMI Adjudication | 0.09 | 0.05 |
The time to first TIMI-adjudicated 4-point MACE (a composite outcome measure of 1. cardiovascular death, 2. non-fatal definite MI, 3. non-fatal definite stroke, or 4. hospitalization for unstable angina) was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First 4-Point MACE Confirmed by TIMI Adjudication | 1.31 | 1.15 |
The time to first TIMI-adjudicated new or presumed new onset atrial fibrillation or atrial flutter was determined for the base study + first extension using a Cox proportional hazards model with terms for treatment, stratum and geographic region. Participants with known history of atrial fibrillation or atrial flutter were excluded and electrocardiogram confirmation was not required. Results are expressed as number of participants with an event per 100 person-years of follow-up. Results from MK-0822-083, a follow up study to the MK-088-018 base study and the double-blind period of the first extension study for participants who discontinued prior to 5 years follow-up, are not included.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Time to First New Onset Atrial Fibrillation or Atrial Flutter Confirmed by TIMI Adjudication | 0.51 | 0.43 |
The incidence rate of femoral shaft fracture events (including both atypical and non-atypical; of any etiology including traumatic) confirmed by adjudication was determined for the base study. Results are expressed as number of participants with an event per 100 person-years of follow-up.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Incidence Rate of Femoral Shaft Fractures Confirmed by Adjudication | 0.10 (0.06 to 0.15) | 0.06 (0.03 to 0.10) |
Atypical subtrochanteric/diaphyseal femoral fractures (AFF) are an uncommon type of low-energy (eg, osteoporotic) femoral shaft fracture of unclear causation infrequently reported in osteoporotic persons treated with long-term anti-resorptive therapy (eg, bisphosphonates). All femoral (femur, femur-distal, femur-shaft) fractures in the base study were adjudicated against both ASBMR 2010 and 2013 criteria. All 5 major features (ie, location along femoral shaft, no/minimal trauma, transverse/short oblique fracture, non-comminuted, complete/incomplete fracture) were required for ASBMR 2010 AFF case definition; while 4 of 5 major features (ie, no/minimal trauma, substantially transverse orientation at cortical origin with possible oblique orientation medially, non-comminuted/minimally comminuted, complete/incomplete fracture, localized periosteal reaction of lateral cortex) with requirement for location along femoral shaft were required for ASBMR 2013 AFF case definition.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study: Incidence Rate of Atypical Femoral Shaft Fractures Confirmed by Adjudication | 0.02 (0.01 to 0.05) | 0.00 (0.00 to 0.02) |
The incidence rate of femoral shaft fracture events (including both atypical and non-atypical; of any etiology including traumatic) confirmed by adjudication was determined for the base study + first extension. Results are expressed as number of participants with an event per 100 person-years of follow-up.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Incidence Rate of Femoral Shaft Fractures Confirmed by Adjudication | 0.09 (0.06 to 0.13) | 0.02 (0.01 to 0.05) |
Atypical subtrochanteric/diaphyseal femoral fractures (AFF) are an uncommon type of low-energy (eg, osteoporotic) femoral shaft fracture of unclear causation infrequently reported in osteoporotic persons treated with long-term anti-resorptive therapy (eg, bisphosphonates). All femoral (femur, femur-distal, femur-shaft) fractures in the base study + first extension were adjudicated against both ASBMR 2010 \& 2013 criteria. All 5 major features (ie, location along femoral shaft, no/minimal trauma, transverse/short oblique fracture, non-comminuted, complete/incomplete fracture) were required for ASBMR 2010 AFF case definition; while 4 of 5 major features (ie, no/minimal trauma, substantially transverse orientation at cortical origin with possible oblique orientation medially, non-comminuted/minimally comminuted, complete/incomplete fracture, localized periosteal reaction of lateral cortex) with requirement for location along femoral shaft were required for ASBMR 2013 AFF case definition.
| Parts. with event per 100 person-years | Odanacatib 50 mg OW | Placebo |
|---|---|---|
| Base Study + First Extension: Incidence Rate of Atypical Femoral Shaft Fractures Confirmed by Adjudication | 0.03 (0.02 to 0.06) | 0.00 (0.00 to 0.01) |
Collected over Base Study + First Extension treatment groups: Up to approximately 74 months of observation Second Extension treatment groups: Up to approximately 34 months of observation. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Base Study + First Extension: Odanacatib 50 mg OW | 378/8,043 (4.7%) | 2,441/8,043 (30.3%) | 5,659/8,043 (70.4%) |
| Base Study + First Extension: Placebo | 327/8,028 (4.1%) | 2,446/8,028 (30.5%) | 5,624/8,028 (70.1%) |
| Second Extension: Odanacatib 50 mg OW | 86/3,144 (2.7%) | 508/3,144 (16.2%) | 311/3,144 (9.9%) |
| Second Extension: Odanacatib 50 mg OW (Placebo) | 39/2,309 (1.7%) | 376/2,309 (16.3%) | 209/2,309 (9.1%) |
| Event | Base Study + First Extension: Odanacatib 50 mg OW | Base Study + First Extension: Placebo | Second Extension: Odanacatib 50 mg OW | Second Extension: Odanacatib 50 mg OW (Placebo) |
|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 135/8043 | 115/8028 | 12/3144 | 12/2309 |
| PneumoniaInfections and infestations | 117/8043 | 116/8028 | 31/3144 | 19/2309 |
| Hip fractureInjury, poisoning and procedural complications | 55/8043 | 104/8028 | 6/3144 | 6/2309 |
| CataractEye disorders | 98/8043 | 79/8028 | 12/3144 | 9/2309 |
| Atrial fibrillationCardiac disorders | 73/8043 | 80/8028 | 17/3144 | 10/2309 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 79/8043 | 71/8028 | 9/3144 | 8/2309 |
| Radius fractureInjury, poisoning and procedural complications | 66/8043 | 77/8028 | 3/3144 | 6/2309 |
| Cerebrovascular accidentNervous system disorders | 68/8043 | 42/8028 | 8/3144 | 4/2309 |
| DeathGeneral disorders | 66/8043 | 62/8028 | 14/3144 | 4/2309 |
| Femoral neck fractureInjury, poisoning and procedural complications | 29/8043 | 62/8028 | 4/3144 | 9/2309 |
| Event | Base Study + First Extension: Odanacatib 50 mg OW | Base Study + First Extension: Placebo | Second Extension: Odanacatib 50 mg OW | Second Extension: Odanacatib 50 mg OW (Placebo) |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 1724/8043 | 1699/8028 | 311/3144 | 209/2309 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1221/8043 | 1151/8028 | 0/3144 | 0/2309 |
| Back painMusculoskeletal and connective tissue disorders | 1194/8043 | 1136/8028 | 0/3144 | 0/2309 |
| HypertensionVascular disorders | 1104/8043 | 1084/8028 | 0/3144 | 0/2309 |
| NasopharyngitisInfections and infestations | 957/8043 | 938/8028 | 0/3144 | 0/2309 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 785/8043 | 741/8028 | 0/3144 | 0/2309 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 751/8043 | 671/8028 | 0/3144 | 0/2309 |
| Upper respiratory tract infectionInfections and infestations | 644/8043 | 596/8028 | 0/3144 | 0/2309 |
| DiarrhoeaGastrointestinal disorders | 589/8043 | 504/8028 | 0/3144 | 0/2309 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 518/8043 | 461/8028 | 0/3144 | 0/2309 |
| Age, Continuous(Years) | Odanacatib 50 mg OW | Placebo | Total |
|---|---|---|---|
| Mean | 72.8 ± 5.4 | 72.9 ± 5.3 | 72.8 ± 5.3 |
| Sex: Female, Male(Participants) | Odanacatib 50 mg OW | Placebo | Total |
|---|---|---|---|
| Female | 8043 | 8028 | 16071 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Odanacatib 50 mg OW | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 97 | 88 | 185 |
| Asian | 1421 | 1411 | 2832 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 129 | 132 | 261 |
| White | 4528 | 4557 | 9085 |
| More than one race | 1867 | 1839 | 3706 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Stratum(Participants) | Odanacatib 50 mg OW | Placebo | Total |
|---|---|---|---|
| Prior Vertebral Fracture | 3733 | 3737 | 7470 |
| No Prior Vertebral Fracture | 4310 | 4291 | 8601 |
| Bisphosphonate-Intolerant(Participants) | Odanacatib 50 mg OW | Placebo | Total |
|---|---|---|---|
| Yes | 1423 | 1447 | 2870 |
| No | 6615 | 6574 | 13189 |
| Data N/A | 5 | 7 | 12 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC